{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:48:28Z","timestamp":1794354508515,"version":"4.9.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003125","name":"Suomen Kulttuurirahasto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003127","name":"Punainen Risti Veripalvelu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003127","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["OC220391"],"award-info":[{"award-number":["OC220391"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune checkpoint inhibitors have demonstrated modest efficacy as a monotherapy in ovarian cancer. Originally developed to improve efficacy of T-cell therapies such as immune checkpoint inhibitors and adoptive cell transfer, TILT-123 (Ad5\/3-E2F-D24-hTNF\u03b1-IRES-hIL-2) is a serotype chimeric oncolytic adenovirus encoding tumor necrosis factor alpha and interleukin-2. Here we report results from phase 1a of PROTA, a single-arm, multicentre dose escalation trial with TILT-123 and pembrolizumab in female patients with platinum resistant or refractory ovarian cancer (NCT05271318). The primary endpoint was safety. Secondary endpoints included efficacy, tolerability, virus persistence and anti-viral immunity. Patients (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200915) received intravenous and intraperitoneal and\/or intratumoral injections of TILT-123 as well as intravenous pembrolizumab. Treatment was well tolerated, and no dose-limiting toxicities were observed. The most frequent adverse events were fever (40%), fatigue (40%) and nausea (40%). Disease control was achieved in 64% of evaluable patients (9\/14). Median progression-free survival and overall survival were 98 and 190 days respectively. Clinical responses were associated with higher serum anti-adenovirus neutralizing antibody titer at baseline and post-treatment. The phase 1b investigating TILT-123, pembrolizumab and PEGylated liposomal doxorubicin in a similar patient population is underway.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-56482-w","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T10:48:47Z","timestamp":1738752527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-4219","authenticated-orcid":false,"given":"Matthew Stephen","family":"Block","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Hugo Armstrong","family":"Clubb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"M\u00e4enp\u00e4\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6235-8612","authenticated-orcid":false,"given":"Santeri","family":"Pakola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafne Carolina Alves","family":"Quixabeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Kudling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0606-6577","authenticated-orcid":false,"given":"Elise","family":"Jirovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5170-5611","authenticated-orcid":false,"given":"Lyna","family":"Haybout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirte","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanae","family":"Zahraoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Gr\u00f6nberg-V\u00e4h\u00e4-Koskela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sini","family":"Raatikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saru","family":"Basnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9336-7920","authenticated-orcid":false,"given":"Nea","family":"Ojala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9652-7373","authenticated-orcid":false,"given":"Teijo","family":"Pellinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabrita","family":"Hemmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-7589","authenticated-orcid":false,"given":"Katja","family":"V\u00e4lim\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annukka","family":"Pasanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1649-9040","authenticated-orcid":false,"given":"Tuomo","family":"Alanko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1420-7785","authenticated-orcid":false,"given":"Daniel","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1992-1251","authenticated-orcid":false,"given":"Jorma","family":"Sormunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Kononen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Wanda","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8629-8232","authenticated-orcid":false,"given":"Michael Jon","family":"Chisamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Goldfinch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvi","family":"Sorsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7926-5285","authenticated-orcid":false,"given":"Riikka","family":"Havunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kistler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aino","family":"Kalervo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Cervera-Carrascon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Manuel","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-8530","authenticated-orcid":false,"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"56482_CR1","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/ijc.34002","volume":"151","author":"CJ Cabasag","year":"2022","unstructured":"Cabasag, C. J. et al. Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020. Int. J. Cancer 151, 1535\u20131541 (2022).","journal-title":"Int. J. Cancer"},{"key":"56482_CR2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","volume":"22","author":"LE Kandalaft","year":"2022","unstructured":"Kandalaft, L. E., Dangaj Laniti, D. & Coukos, G. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat. Rev. Cancer 22, 640\u2013656 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"56482_CR3","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis, U. A. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol. 30, 1080\u20131087 (2019).","journal-title":"Ann. Oncol."},{"key":"56482_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","volume":"18","author":"K Harrington","year":"2019","unstructured":"Harrington, K., Freeman, D. J., Kelly, B., Harper, J. & Soria, J. C. Optimizing oncolytic virotherapy in cancer treatment. Nat. Rev. Drug Discov. 18, 689\u2013706 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"56482_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00922-1","volume":"13","author":"O Hemminki","year":"2020","unstructured":"Hemminki, O., Dos Santos, J. M. & Hemminki, A. Oncolytic viruses for cancer immunotherapy. J. Hematol. Oncol. 13, 1\u201315 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"56482_CR6","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/mt.2015.125","volume":"23","author":"A Koski","year":"2015","unstructured":"Koski, A. et al. Biodistribution analysis of oncolytic adenoviruses in patient autopsy samples reveals vascular transduction of noninjected tumors and tissues. Mol. Ther. 23, 1641\u20131652 (2015).","journal-title":"Mol. Ther."},{"key":"56482_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/mt.2014.218","volume":"23","author":"A Kanerva","year":"2015","unstructured":"Kanerva, A. et al. Case\u2013control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors. Mol. Ther. 23, 321\u2013329 (2015).","journal-title":"Mol. Ther."},{"key":"56482_CR8","doi-asserted-by":"publisher","first-page":"e0131242","DOI":"10.1371\/journal.pone.0131242","volume":"10","author":"S T\u00e4htinen","year":"2015","unstructured":"T\u00e4htinen, S. et al. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PLoS ONE 10, e0131242 (2015).","journal-title":"PLoS ONE"},{"key":"56482_CR9","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/2326-6066.CIR-14-0220-T","volume":"3","author":"S T\u00e4htinen","year":"2015","unstructured":"T\u00e4htinen, S. et al. Adenovirus improves the efficacy of adoptive T-cell therapy by recruiting immune cells to and promoting their activity at the tumor. Cancer Immunol. Res. 3, 915\u2013925 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"56482_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","volume":"4","author":"R Havunen","year":"2017","unstructured":"Havunen, R. et al. Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive cell therapy. Mol. Ther.-Oncolytics 4, 77\u201386 (2017).","journal-title":"Mol. Ther.-Oncolytics"},{"key":"56482_CR11","doi-asserted-by":"publisher","first-page":"1761229","DOI":"10.1080\/2162402X.2020.1761229","volume":"9","author":"V Cervera-Carrascon","year":"2020","unstructured":"Cervera-Carrascon, V. et al. Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. Oncoimmunology 9, 1761229 (2020).","journal-title":"Oncoimmunology"},{"key":"56482_CR12","doi-asserted-by":"publisher","first-page":"706517","DOI":"10.3389\/fimmu.2021.706517","volume":"12","author":"V Cervera-Carrascon","year":"2021","unstructured":"Cervera-Carrascon, V. et al. Adenovirus armed with TNF\u03b1 and IL2 added to aPD-1 regimen mediates antitumor efficacy in tumors refractory to aPD-1. Front. Immunol. 12, 706517 (2021).","journal-title":"Front. Immunol."},{"key":"56482_CR13","doi-asserted-by":"publisher","first-page":"794251","DOI":"10.3389\/fimmu.2022.794251","volume":"13","author":"JH Clubb","year":"2022","unstructured":"Clubb, J. H. et al. Adenovirus encoding tumor necrosis factor alpha and interleukin 2 induces a tertiary lymphoid structure signature in immune checkpoint inhibitor refractory head and neck cancer. Front. Immunol. 13, 794251 (2022).","journal-title":"Front. Immunol."},{"key":"56482_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/diseases10030052","volume":"10","author":"C Heini\u00f6","year":"2022","unstructured":"Heini\u00f6, C. et al. Effective combination immunotherapy with oncolytic adenovirus and anti-PD-1 for treatment of human and murine ovarian cancers. Diseases 10, 52 (2022).","journal-title":"Diseases"},{"key":"56482_CR15","doi-asserted-by":"publisher","first-page":"1060540","DOI":"10.3389\/fimmu.2023.1060540","volume":"14","author":"JH Clubb","year":"2023","unstructured":"Clubb, J. H. et al. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting. Front. Immunol. 14, 1060540 (2023).","journal-title":"Front. Immunol."},{"key":"56482_CR16","doi-asserted-by":"publisher","first-page":"2241710","DOI":"10.1080\/2162402X.2023.2241710","volume":"12","author":"TV Kudling","year":"2023","unstructured":"Kudling, T. V. et al. Effective intravenous delivery of adenovirus armed with TNF\u03b1 and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer. OncoImmunology 12, 2241710 (2023).","journal-title":"OncoImmunology"},{"key":"56482_CR17","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3390\/cells9040798","volume":"9","author":"C Heini\u00f6","year":"2020","unstructured":"Heini\u00f6, C. et al. TNF\u03b1 and IL2 encoding oncolytic adenovirus activates pathogen and danger-associated immunological signaling. Cells 9, 798 (2020).","journal-title":"Cells"},{"key":"56482_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0623-z","volume":"7","author":"RH Andtbacka","year":"2019","unstructured":"Andtbacka, R. H. et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma. J. Immunother. Cancer 7, 1\u201311 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"56482_CR19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/JCO.22.00343","volume":"41","author":"JA Chesney","year":"2023","unstructured":"Chesney, J. A. et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J. Clin. Oncol. 41, 528\u2013540 (2023).","journal-title":"J. Clin. Oncol."},{"key":"56482_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","volume":"610","author":"L Codarri Deak","year":"2022","unstructured":"Codarri Deak, L. et al. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. Nature 610, 161\u2013172 (2022).","journal-title":"Nature"},{"key":"56482_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","volume":"610","author":"M Hashimoto","year":"2022","unstructured":"Hashimoto, M. et al. PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program. Nature 610, 173\u2013181 (2022).","journal-title":"Nature"},{"key":"56482_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.omto.2020.03.003","volume":"17","author":"V Cervera-Carrascon","year":"2020","unstructured":"Cervera-Carrascon, V. et al. Comparison of clinically relevant oncolytic virus platforms for enhancing T cell therapy of solid tumors. Mol. Ther.-Oncolytics 17, 47\u201360 (2020).","journal-title":"Mol. Ther.-Oncolytics"},{"key":"56482_CR23","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1002\/cncr.30736","volume":"123","author":"KN Moore","year":"2017","unstructured":"Moore, K. N. et al. Phase 1 dose\u2010escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor \u03b1\u2010targeting antibody\u2010drug conjugate, in patients with solid tumors. Cancer 123, 3080\u20133087 (2017).","journal-title":"Cancer"},{"key":"56482_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/mt.2011.230","volume":"20","author":"A Koski","year":"2012","unstructured":"Koski, A. et al. Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Mol. Ther. 20, 221\u2013229 (2012).","journal-title":"Mol. Ther."},{"key":"56482_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s13046-024-03219-0","volume":"43","author":"E Jirovec","year":"2024","unstructured":"Jirovec, E. et al. Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors. J. Exp. Clin. Cancer Res. 43, 297 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"56482_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","volume":"623","author":"AL Ling","year":"2023","unstructured":"Ling, A. L. et al. Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature 623, 157\u2013166 (2023).","journal-title":"Nature"},{"key":"56482_CR27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"56482_CR28","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke, L. et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat. Cancer 2, 794\u2013802 (2021).","journal-title":"Nat. Cancer"},{"key":"56482_CR29","doi-asserted-by":"crossref","unstructured":"Lu, H. et al. Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer. Cell Rep. Med. 4, 101092 (2023).","DOI":"10.1016\/j.xcrm.2023.101092"},{"key":"56482_CR30","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1158\/1078-0432.CCR-12-0234","volume":"18","author":"JS Nielsen","year":"2012","unstructured":"Nielsen, J. S. et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27\u2212 memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin. Cancer Res. 18, 3281\u20133292 (2012).","journal-title":"Clin. Cancer Res."},{"key":"56482_CR31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41586-020-03144-0","volume":"591","author":"S Biswas","year":"2021","unstructured":"Biswas, S. et al. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature 591, 464\u2013470 (2021).","journal-title":"Nature"},{"key":"56482_CR32","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.cell.2022.02.012","volume":"185","author":"RD Mazor","year":"2022","unstructured":"Mazor, R. D. et al. Tumor-reactive antibodies evolve from non-binding and autoreactive precursors. Cell 185, 1208\u20131222 (2022).","journal-title":"Cell"},{"key":"56482_CR33","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/107327481402100304","volume":"21","author":"AR Hansen","year":"2014","unstructured":"Hansen, A. R., Graham, D. M., Pond, G. R. & Siu, L. L. Phase 1 trial design: is 3+ 3 the best? Cancer Control 21, 200\u2013208 (2014).","journal-title":"Cancer Control"},{"key":"56482_CR34","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/djp079","volume":"101","author":"C Le Tourneau","year":"2009","unstructured":"Le Tourneau, C., Lee, J. J. & Siu, L. L. Dose escalation methods in phase I cancer clinical trials. JNCI: J. Natl. Cancer Inst. 101, 708\u2013720 (2009).","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"56482_CR35","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1158\/1078-0432.CCR-09-1961","volume":"16","author":"SP Ivy","year":"2010","unstructured":"Ivy, S. P., Siu, L. L., Garrett-Mayer, E. & Rubinstein, L. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin. Cancer Res. 16, 1726\u20131736 (2010).","journal-title":"Clin. Cancer Res."},{"key":"56482_CR36","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1089\/10430340260185139","volume":"13","author":"A Hemminki","year":"2002","unstructured":"Hemminki, A. et al. Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Hum. Gene Ther. 13, 1505\u20131514 (2002).","journal-title":"Hum. Gene Ther."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56482-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56482-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56482-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T10:48:51Z","timestamp":1738752531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56482-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["56482"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-56482-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.H. is shareholder in Circio Holdings ASA. A.H., A.K., C.K., J.H.A.C., J.S., D.C.A.Q., S.S., R.H., L.H., and V.C.C. are employees and shareholders in TILT Biotherapeutics Oy. MJC is an employee and shareholder in Merck & Co., Inc. M.S.B. is on the TILT Biotherapeutics Scientific Advisory Board. Other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1381"}}